Side-by-side comparison of AI visibility scores, market position, and capabilities
AI pharma drug launch platform compressing market access research from months to minutes; six-figure ARR within weeks of launch with Bayer as client across 12 markets.
Cellbyte is an AI-powered pharmaceutical drug launch platform that accelerates global drug launches by providing real-time pricing and market access intelligence — compressing processes that traditionally take months or years (reference pricing analysis, health technology assessment research, payer landscape mapping) into minutes using AI-driven data aggregation and analysis. Founded in 2024 and a Y Combinator graduate, Cellbyte raised $2.75 million in seed funding led by Frontline Ventures and Y Combinator, achieving six-figure ARR within weeks of launch.\n\nCellbyte's platform aggregates regulatory approval data, drug pricing reference lists, payer coverage policies, and health technology assessment outcomes across multiple countries to help pharmaceutical market access teams make faster, better-informed launch sequence decisions. Global drug launches require navigating distinct pricing and reimbursement systems in each country — reference pricing (where one country's price affects another's) makes launch sequencing strategically critical and data-intensive. Cellbyte automates the research that market access consultants previously performed manually.\n\nIn 2025, Cellbyte secured major clients including Bayer across 12 live markets — demonstrating enterprise adoption velocity unusual for a seed-stage company. The pharmaceutical market access software market includes specialized players like IQVIA (market data), ZS Associates (consulting), and early-stage AI entrants. The total addressable market is substantial given the global pharmaceutical market's hundreds of billions in annual drug launches. Cellbyte's 2025-2026 strategy focuses on expanding the breadth of markets covered (targeting all major pharma markets globally), deepening AI capabilities for predictive pricing modeling, and growing its pharmaceutical client base beyond the initial anchor customers.
US YC W20 AI interior design platform with style preference discovery and room visualization; generating personalized moodboards and shoppable décor matches competing with Houzz for AI-native home design discovery.
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal design aesthetic, visualize how spaces would look with different furniture and décor, and find matching products from online retailers. Users select style preferences (mid-century modern, bohemian, minimalist, coastal) and color palettes (navy, salmon, olive, beige) and receive AI-generated moodboards and room transformation visuals in seconds — with the platform linking out to purchasable products that match the visualized design. Founded in 2020 and enhanced with more sophisticated AI algorithms in 2024-2025, Oda Studio serves the design discovery and product-matching need that exists in the early stages of home decorating before interior designers are typically engaged.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.